GlassScriptPhysician profile
Lea Marie Davis
NPI 1730802950
$430.37
in general payments reported to CMS, 2019-2025
14 companies · $48.83 in 2025
The $48.83 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $382 · 2025: $48.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.79 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $72.93 | 2023 | Quviviq |
| Pfizer INC. | $31.80 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.08 | 2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $28.30 | 2023 | Mounjaro |
| Dynavax Technologies Corporation | $19.72 | 2023 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $19.31 | 2023 | Farxiga |
| Lucid Diagnostics INC. | $18.39 | 2023 | |
| Axsome Therapeutics, INC. | $18.22 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $17.24 | 2023 | |
| Sumitomo Pharma America, INC. | $15.00 | 2023 | Gemtesa |
| Astellas Pharma US INC | $14.39 | 2023 | Veozah |
| Novo Nordisk INC | $14.06 | 2023 | Ozempic, Rybelsus |
| Organon LLC | $9.14 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.